COAG vs DBVT: fair value comparison
Hemab Therapeutics Holdings, Inc. and DBV Technologies S.A. · Updated 2026-10-19
COAG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DBVT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, COAG currently ranks higher by quality score.
| COAG | DBVT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $30.07 | $9.05 |
| 12-month range | $27.13–$45.00 | $8.87–$24.54 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #231 of 301 Healthcare | #233 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: COAG fair value analysis · DBVT fair value analysis